Programme 2025
Day 1: Thursday. 13:00 – 17:30
13:00 – 13:10
Welcome and Introduction
Giuseppe Luigi Banna (UK) & Ravindran Kanesvaran (Singapore)
Prostate Cancer (1h)
Chair: Ravindran Kanesvaran (Singapore) Discussant: Elena Castro (Spain)
13:10 – 13:30
Toward precision oncology
Neeraj Agarwal (US)
13:30 – 13:50
Theragnostic revolution
Partha S. Choudhary (India)
13:50 – 14:10
Translating trial endpoints into clinically meaningful decisions
Alison Tree (UK)
14:10 – 14:50
Symposia
14:50 – 15:10
Coffee Break
15:10 – 15:30
Symposia
Rare & GU other matters (1h 20)
Chair: Giuseppe L. Banna (UK) Discussant: Simon Crabb (UK)
15:30 – 15:50
Minimising toxicity in testicular cancer
Pasquale Rescigno (UK)
15:50 – 16:20
Treatment breaks in GU Cancer: Is it safe?
Renal
Sara Elena Rebuzzi (Italy)
Bladder
Simon Crabb (UK)
16:20 – 16:40
MDTs: Gold Standard or Bottleneck in Urological Cancer Care?
Ben Lamb (UK)
Poster Award
Chair: Ravindran Kanesvaran (Singapore)
Discussant: Matteo Santoni (Italy)
16:40 – 16:55
Poster award
TBC
16:55 – 17:10
Selected poster discussion
Aruni Ghose (UK)
Day 2: Friday 09:00 – 13:10
09:00 – 09:10
Introduction
Bladder (1h)
Chair: Ravindran Kanesvaran (Singapore) Discussant: Param Mariappan (UK)
09:10 – 09:30
How perioperative treatment is evolving
Petros Grivas (US)
09:30 – 9:50
Getting more patients to the right 1st line of treatment
Enrique Grande (Spain)
09:50 – 10:10
Histology subtypes in bladder cancer; have they been left behind
Stefanie Zschäbitz (Germany)
10:10 – 10:50
Symposia
10:50 – 11:20
Coffee Break – (ePoster Session)
Renal Cancer (1h)
Chair: Giuseppe Banna (UK) Discussant: Amit Bahl (UK)
11:20 – 11:40
Evolution of adjuvant therapy and impact on relapse
Sumanta Kumar Pal (US)
11:40 – 12:00
Current and emerging predictive biomarkers
Laurence Albiges (France)
12:00 – 12:20
SABRability
John McGrane (UK)
Clinical Case Quiz (20min)
Chair: Ravindran Kanesvaran (Singapore) Discussant: Yüksel Ürün (Turkey)
12:20 – 12:40
Polls and questions
María Natalia Gandur Quiroga (Argentina)
12:40 – 13:00
Polls and questions
Akash Maniam (UK)